Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Sunitinib in Cytokine-Refractory Metastatic RCC
NCT00137423Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2005
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC), sponsored by Pfizer. Primary endpoint: Objective Response Rate up to 1 year. Started May 2005; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00137423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137423.